Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Severe exacerbations in moderate-to-severe asthmatics are associated with increased pro-inflammatory and type 1 mediators in sputum and serum.

Ghebre MA, Pang PH, Desai D, Hargadon B, Newby C, Woods J, Rapley L, Cohen SE, Herath A, Gaillard EA, May RD, Brightling CE.

BMC Pulm Med. 2019 Aug 8;19(1):144. doi: 10.1186/s12890-019-0906-7.

2.

Cohort profile: Extended Cohort for E-health, Environment and DNA (EXCEED).

John C, Reeve NF, Free RC, Williams AT, Ntalla I, Farmaki AE, Bethea J, Barton LM, Shrine N, Batini C, Packer R, Terry S, Hargadon B, Wang Q, Melbourne CA, Adams EL, Bee CE, Harrington K, Miola J, Brunskill NJ, Brightling CE, Barwell J, Wallace SE, Hsu R, Shepherd DJ, Hollox EJ, Wain LV, Tobin MD.

Int J Epidemiol. 2019 Jul 31. pii: dyz175. doi: 10.1093/ije/dyz175. [Epub ahead of print] No abstract available.

PMID:
31365084
3.

Lung Computational Models and the Role of the Small Airways in Asthma.

Foy BH, Soares M, Bordas R, Richardson M, Bell A, Singapuri A, Hargadon B, Brightling C, Burrowes K, Kay D, Owers-Bradley J, Siddiqui S.

Am J Respir Crit Care Med. 2019 May 18. doi: 10.1164/rccm.201812-2322OC. [Epub ahead of print]

PMID:
31106566
4.

Cohort Profile: Extended Cohort for E-health, Environment and DNA (EXCEED).

John C, Reeve NF, Free RC, Williams AT, Ntalla I, Farmaki AE, Bethea J, Barton LM, Shrine N, Batini C, Packer R, Terry S, Hargadon B, Wang Q, Melbourne CA, Adams EL, Bee CE, Harrington K, Miola J, Brunskill NJ, Brightling CE, Barwell J, Wallace SE, Hsu R, Shepherd DJ, Hollox EJ, Wain LV, Tobin MD.

Int J Epidemiol. 2019 Jun 1;48(3):678-679j. doi: 10.1093/ije/dyz073. No abstract available.

5.

Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study.

Ibrahim W, Wilde M, Cordell R, Salman D, Ruszkiewicz D, Bryant L, Richardson M, Free RC, Zhao B, Yousuf A, White C, Russell R, Jones S, Patel B, Awal A, Phillips R, Fowkes G, McNally T, Foxon C, Bhatt H, Peltrini R, Singapuri A, Hargadon B, Suzuki T, Ng LL, Gaillard E, Beardsmore C, Ryanna K, Pandya H, Coates T, Monks PS, Greening N, Brightling CE, Thomas P, Siddiqui S.

BMJ Open. 2019 Mar 8;9(3):e025486. doi: 10.1136/bmjopen-2018-025486.

6.

Exacerbations of severe asthma in patients treated with mepolizumab.

Shrimanker R, Pavord ID, Yancey S, Heaney LG, Green RH, Bradding P, Hargadon B, Brightling CE, Wardlaw AJ, Haldar P.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801127. doi: 10.1183/13993003.01127-2018. Print 2018 Dec. No abstract available.

PMID:
30464012
7.

Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis.

Siddiqui S, Shikotra A, Richardson M, Doran E, Choy D, Bell A, Austin CD, Eastham-Anderson J, Hargadon B, Arron JR, Wardlaw A, Brightling CE, Heaney LG, Bradding P.

J Allergy Clin Immunol. 2018 Nov;142(5):1457-1468. doi: 10.1016/j.jaci.2017.12.982. Epub 2018 Mar 14.

PMID:
29550052
8.

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.

Bilocca D, Hargadon B, Pavord ID, Green RH, Brightling CE, Bradding P, Wardlaw AJ, Martin N, Murphy AC, Siddiqui S.

Chron Respir Dis. 2018 Feb;15(1):85-87. doi: 10.1177/1479972317709650. Epub 2017 Jun 1.

9.

Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation.

Sousa AR, Marshall RP, Warnock LC, Bolton S, Hastie A, Symon F, Hargadon B, Marshall H, Richardson M, Brightling CE, Haldar P, Milone R, Chalk P, Williamson R, Panettieri R Jr, Knowles R, Bleecker ER, Wardlaw AJ.

Clin Exp Allergy. 2017 Jul;47(7):890-899. doi: 10.1111/cea.12954. Epub 2017 Jun 16.

PMID:
28493293
10.

A CEACAM6-High Airway Neutrophil Phenotype and CEACAM6-High Epithelial Cells Are Features of Severe Asthma.

Shikotra A, Choy DF, Siddiqui S, Arthur G, Nagarkar DR, Jia G, Wright AK, Ohri CM, Doran E, Butler CA, Hargadon B, Abbas AR, Jackman J, Wu LC, Heaney LG, Arron JR, Bradding P.

J Immunol. 2017 Apr 15;198(8):3307-3317. doi: 10.4049/jimmunol.1600606. Epub 2017 Mar 8.

11.

Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography.

Subramanian DR, Gupta S, Burggraf D, Vom Silberberg SJ, Heimbeck I, Heiss-Neumann MS, Haeussinger K, Newby C, Hargadon B, Raj V, Singh D, Kolsum U, Hofer TP, Al-Shair K, Luetzen N, Prasse A, Müller-Quernheim J, Benea G, Leprotti S, Boschetto P, Gorecka D, Nowinski A, Oniszh K, Castell WZ, Hagen M, Barta I, Döme B, Strausz J, Greulich T, Vogelmeier C, Koczulla AR, Gut I, Hohlfeld J, Welte T, Lavae-Mokhtari M, Ziegler-Heitbrock L, Brightling C, Parr DG.

Eur Respir J. 2016 Jul;48(1):92-103. doi: 10.1183/13993003.01878-2015. Epub 2016 May 26.

12.

TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma.

Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E, Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P.

Sci Transl Med. 2015 Aug 19;7(301):301ra129. doi: 10.1126/scitranslmed.aab3142.

PMID:
26290411
13.

Temporal assessment of airway remodeling in severe asthma using quantitative computed tomography.

Gupta S, Hartley R, Singapuri A, Hargadon B, Monteiro W, Pavord ID, Sousa AR, Marshall RP, Subramanian D, Parr D, Entwisle JJ, Siddiqui S, Raj V, Brightling CE.

Am J Respir Crit Care Med. 2015 Jan 1;191(1):107-10. doi: 10.1164/rccm.201406-1128LE. No abstract available.

14.

Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study.

Wilson E, McKeever T, Hargadon B, Hearson G, Anderson J, Hodgson D, Bailey H, Meakin G, Thomas M, Pavord ID, Harrison T, Shaw D.

Eur Respir J. 2014 Dec;44(6):1705-7. doi: 10.1183/09031936.00093614. Epub 2014 Aug 19. No abstract available.

15.

COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils.

Eltboli O, Bafadhel M, Hollins F, Wright A, Hargadon B, Kulkarni N, Brightling C.

BMC Pulm Med. 2014 Jul 9;14:112. doi: 10.1186/1471-2466-14-112.

16.

Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma.

Newby C, Agbetile J, Hargadon B, Monteiro W, Green R, Pavord I, Brightling C, Siddiqui S.

J Allergy Clin Immunol. 2014 Aug;134(2):287-94. doi: 10.1016/j.jaci.2014.04.005. Epub 2014 Jun 11.

PMID:
24928647
17.

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

Haldar P, Brightling CE, Singapuri A, Hargadon B, Gupta S, Monteiro W, Bradding P, Green RH, Wardlaw AJ, Ortega H, Pavord ID.

J Allergy Clin Immunol. 2014 Mar;133(3):921-3. doi: 10.1016/j.jaci.2013.11.026. Epub 2014 Jan 10. No abstract available.

PMID:
24418480
18.

Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study).

Agbetile J, Bourne M, Fairs A, Hargadon B, Desai D, Broad C, Morley J, Bradding P, Brightling CE, Green RH, Haldar P, Pashley CH, Pavord ID, Wardlaw AJ.

J Allergy Clin Immunol. 2014 Jul;134(1):33-9. doi: 10.1016/j.jaci.2013.09.050. Epub 2013 Nov 28.

PMID:
24290286
19.

Quantitative computed tomography-derived clusters: redefining airway remodeling in asthmatic patients.

Gupta S, Hartley R, Khan UT, Singapuri A, Hargadon B, Monteiro W, Pavord ID, Sousa AR, Marshall RP, Subramanian D, Parr D, Entwisle JJ, Siddiqui S, Raj V, Brightling CE.

J Allergy Clin Immunol. 2014 Mar;133(3):729-38.e18. doi: 10.1016/j.jaci.2013.09.039. Epub 2013 Nov 12.

20.

Isolation of Aspergillus fumigatus from sputum is associated with elevated airborne levels in homes of patients with asthma.

Fairs A, Agbetile J, Bourne M, Hargadon B, Monteiro WR, Morley JP, Edwards RE, Wardlaw AJ, Pashley CH.

Indoor Air. 2013 Aug;23(4):275-84. doi: 10.1111/ina.12020. Epub 2013 Jan 25.

PMID:
23198683
21.

A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma.

Shaw D, Green R, Berry M, Mellor S, Hargadon B, Shelley M, McKenna S, Thomas M, Pavord I.

Prim Care Respir J. 2012 Sep;21(3):283-7. doi: 10.4104/pcrj.2012.00057.

22.

Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV1.

Agbetile J, Fairs A, Desai D, Hargadon B, Bourne M, Mutalithas K, Edwards R, Morley JP, Monteiro WR, Kulkarni NS, Green RH, Pavord ID, Bradding P, Brightling CE, Wardlaw AJ, Pashley CH.

Clin Exp Allergy. 2012 May;42(5):782-91. doi: 10.1111/j.1365-2222.2012.03987.x.

23.

Airway dysfunction and inflammation in pool- and non-pool-based elite athletes.

Martin N, Lindley MR, Hargadon B, Monteiro WR, Pavord ID.

Med Sci Sports Exerc. 2012 Aug;44(8):1433-9. doi: 10.1249/MSS.0b013e31824c823c.

PMID:
22297809
24.

Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma.

Shikotra A, Choy DF, Ohri CM, Doran E, Butler C, Hargadon B, Shelley M, Abbas AR, Austin CD, Jackman J, Wu LC, Heaney LG, Arron JR, Bradding P.

J Allergy Clin Immunol. 2012 Jan;129(1):104-11.e1-9. doi: 10.1016/j.jaci.2011.08.031. Epub 2011 Oct 5.

PMID:
21975173
25.

Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease.

Bafadhel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B, Mistry V, Reid C, Parker D, Dodson P, Jenkins M, Lloyd A, Rugman P, Newbold P, Brightling CE.

Respiration. 2012;83(1):36-44. doi: 10.1159/000330667. Epub 2011 Sep 7.

26.

Body mass and fat mass in refractory asthma: an observational 1 year follow-up study.

Bafadhel M, Singapuri A, Terry S, Hargadon B, Monteiro W, Green RH, Bradding PH, Wardlaw AJ, Pavord ID, Brightling CE.

J Allergy (Cairo). 2010;2010:251758. doi: 10.1155/2010/251758. Epub 2010 Dec 1.

27.

IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma.

Fairs A, Agbetile J, Hargadon B, Bourne M, Monteiro WR, Brightling CE, Bradding P, Green RH, Mutalithas K, Desai D, Pavord ID, Wardlaw AJ, Pashley CH.

Am J Respir Crit Care Med. 2010 Dec 1;182(11):1362-8. doi: 10.1164/rccm.201001-0087OC. Epub 2010 Jul 16.

28.

Mepolizumab and exacerbations of refractory eosinophilic asthma.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.

N Engl J Med. 2009 Mar 5;360(10):973-84. doi: 10.1056/NEJMoa0808991. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

29.

Association between neutrophilic airway inflammation and airflow limitation in adults with asthma.

Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, Brightling CE, Wardlaw AJ, Pavord ID.

Chest. 2007 Dec;132(6):1871-5. Epub 2007 Oct 9.

PMID:
17925424
30.

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID.

Eur Respir J. 2007 May;29(5):906-13. Epub 2007 Feb 14.

31.

Evidence of a role of tumor necrosis factor alpha in refractory asthma.

Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID.

N Engl J Med. 2006 Feb 16;354(7):697-708.

32.

Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness.

Green RH, Brightling CE, McKenna S, Hargadon B, Neale N, Parker D, Ruse C, Hall IP, Pavord ID.

Eur Respir J. 2006 Jun;27(6):1144-51. Epub 2006 Feb 2.

33.

Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma.

Berry M, Hargadon B, Morgan A, Shelley M, Richter J, Shaw D, Green RH, Brightling C, Wardlaw AJ, Pavord ID.

Eur Respir J. 2005 Jun;25(6):986-91.

34.

Observational study of the natural history of eosinophilic bronchitis.

Berry MA, Hargadon B, McKenna S, Shaw D, Green RH, Brightling CE, Wardlaw AJ, Pavord ID.

Clin Exp Allergy. 2005 May;35(5):598-601.

PMID:
15898981
35.

Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis.

Lawley W, Hird H, Mallinder P, McKenna S, Hargadon B, Murray A, Bradding P.

Mutat Res. 2005 May 2;572(1-2):1-13.

PMID:
15790486
36.

Sputum eosinophilia in idiopathic pulmonary fibrosis.

Birring SS, Parker D, McKenna S, Hargadon B, Brightling CE, Pavord ID, Bradding P.

Inflamm Res. 2005 Feb;54(2):51-6.

PMID:
15750711
37.

Airway function and markers of airway inflammation in patients with treated hypothyroidism.

Birring SS, Patel RB, Parker D, McKenna S, Hargadon B, Monteiro WR, Falconer Smith JF, Pavord ID.

Thorax. 2005 Mar;60(3):249-53.

38.

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, Bradding P.

Thorax. 2005 Mar;60(3):193-8.

39.

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID.

Lancet. 2002 Nov 30;360(9347):1715-21.

PMID:
12480423

Supplemental Content

Loading ...
Support Center